eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2023
vol. 40
 
Share:
Send email
Share:
abstract:
Original paper

Changes in eotaxin-3 and pulmonary and activationregulated chemokine levels in patients after dupilumab treatment: a systematic review and meta-analysis

Leyi Wang
1
,
Haiyan Cheng
1
,
Boyang Zhou
1
,
Linfeng Li
1

  1. Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Adv Dermatol Allergol 2023; XL (5): 670-678
DOI: https://doi.org/10.5114/ada.2023.132231
Online publish date: 2023/11/09
View full text Get citation
 
Introduction:
Dupilumab is approved for a variety of type 2 inflammatory diseases. Changes in chemokine levels during treatment require further analysis.

Aim:
We evaluated changes in eotaxin-3 and PARC levels after dupilumab treatment through a meta-analysis, aiming to provide more comprehensive results.

Material and methods:
Databases were searched to select eligible publications. The study quality was assessed after inclusion. The standardized mean difference (SMD) was used for evaluation.

Results:
Four studies were included. Eotaxin-3 levels were not seen significantly decreased at weeks 1 and 12, with SMD = –0.39 (95% CI: –1.78, 0.99) and –2.60 (95% CI: –5.77, 0.57), respectively (p > 0.05). Eotaxin-3 levels decreased significantly at weeks 2, 4, 8, 16, 24, 36, and 52, with SMD = –0.94 (95% CI: –1.61, –0.27); –1.17 (95% CI: –1.49, –0.84); –1.20 (95% CI: –1.52, –0.88); –1.31 (95% CI: –1.83, –0.79); –4.57 (95% CI: –6.90, –2.33); –5.28 (95% CI: –5.52, –5.04); and –4.03 (95% CI: –4.22, –3.85) (p < 0.05), respectively. PARC levels decreased significantly at weeks 4, 8, 12, and 16, with SMD = –1.08 (95% CI: –1.59, –0.58); –1.17 (95% CI: –1.68, –0.66); –1.11 (95% CI: –1.61, –0.60); and –1.15 (95% CI: –1.66, –0.64) (p < 0.05), respectively.

Conclusions:
Eotaxin-3 and PARC levels can be significantly reduced in patients treated with dupilumab.

keywords:

eotaxin-3, PARC, dupilumab, type 2 inflammatory diseases, meta-analysis
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.